Mayne Pharma completes sale of U.S. Generics Portfolio to Dr. Reddy’s

Mayne Pharma’s CEO Mr Shawn Patrick O’Brien said: “The divestiture of our US retail generics portfolio is yet another milestone in the transformation of Mayne Pharma into a specialty pharmaceutical company in the US women’s healthcare and dermatology markets. We are excited by the significant opportunities to drive operational, commercial and financial improvements across our US women’s health and dermatology businesses, as well as in our International business. Our stated objectives remain to return the Company to profitability,to generate operating cash flow that supports further growth and to drive improved returns for our shareholders.”

Learn more